420 with CNW — Research Firm Plans to Study Use of Cannabis as Analgesic
CBD Science Group PLC plans to conduct large-scale trials to evaluate the use of cannabis in managing pain in cancer patients where conventional pain relief isn’t adequate. This will provide an alternative to opioids, which sometimes induce unwanted side effects or interfere with ongoing cancer treatments. Scientists at CBD plan to investigate the use of marijuana-based analgesics, with chief commercial officer Graeme McFarlane stating that the trials will measure the effectiveness and safety of these analgesics in addition to other variables.
McFarlane explained that the company would use various tools including clinician reporting and self-reporting in patients in its evaluations. This is in addition to exploring the health economics of these medicines and evaluating the actual value of these natural medicines.
The company is planning to begin its research in second quarter 2022 after securing a strong supply chain that can meet its trial requirements. The company may have sufficient evidence to present to the regulatory bodies in the United Kingdom by Q2 2023.
McFarlane also stated that before CBD Science Group expanded to other centers in Europe and the United Kingdom, it would begin trials with 100 to 200 patients. He added that this was what was required for an effective strategy.
In addition to this, he explained that the company would not be conducting randomized controlled trials because the planned studies weren’t designed to use larger datasets, in addition to other factors. He noted that a drug performing well in clinical trials didn’t directly translate to it performing well in the real world.
The company expects to release outcome publications during its study period, with company officials noting that this approach will continue improving access for the many individuals suffering from various indications, in addition to offering a tool to educate clinicians.
At the moment, the company is crowd funding to finance early trials, with its objective being to raise £2 million ($2.74 million). In the long term, the CBD Science Group plans to approach the stock market to source for the capital it needs to develop and expand its business.
The company’s team is made up of the lead for cancer at the National Institute for Health Research Professor Sam Ahmedzai and former NHS England deputy medical director Professor Mike Bewick. The team is also comprised of renowned experts in anaesthetics, pharmacology and palliative care. CBD Science Group CEO Dr. Michael Raymont notes that the company’s strategy is unique and has been developed by experts who understand the regulatory framework and want the best for patients.
If this study yields positive outcomes regarding the analgesic attributes of marijuana, the entire cannabis sector including companies such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) will be vindicated in their conviction that the medicinal potential of cannabis is yet to be fully understood.
NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
CBD Science Group PLC plans to conduct large-scale trials to evaluate the use of cannabis in managing pain in cancer patients where conventional pain relief isn’t adequate. This will provide an alternative to opioids, which sometimes induce unwanted side effects or interfere with ongoing cancer treatments. Scientists at CBD plan to investigate the use of marijuana-based analgesics, with chief commercial officer Graeme McFarlane stating that the trials will measure the effectiveness and safety of these analgesics in addition to other variables.
McFarlane explained that the company would use various tools including clinician reporting and self-reporting in patients in its evaluations. This is in addition to exploring the health economics of these medicines and evaluating the actual value of these natural medicines.
The company is planning to begin its research in second quarter 2022 after securing a strong supply chain that can meet its trial requirements. The company may have sufficient evidence to present to the regulatory bodies in the United Kingdom by Q2 2023.
McFarlane also stated that before CBD Science Group expanded to other centers in Europe and the United Kingdom, it would begin trials with 100 to 200 patients. He added that this was what was required for an effective strategy.
In addition to this, he explained that the company would not be conducting randomized controlled trials because the planned studies weren’t designed to use larger datasets, in addition to other factors. He noted that a drug performing well in clinical trials didn’t directly translate to it performing well in the real world.
The company expects to release outcome publications during its study period, with company officials noting that this approach will continue improving access for the many individuals suffering from various indications, in addition to offering a tool to educate clinicians.
At the moment, the company is crowd funding to finance early trials, with its objective being to raise £2 million ($2.74 million). In the long term, the CBD Science Group plans to approach the stock market to source for the capital it needs to develop and expand its business.
The company’s team is made up of the lead for cancer at the National Institute for Health Research Professor Sam Ahmedzai and former NHS England deputy medical director Professor Mike Bewick. The team is also comprised of renowned experts in anaesthetics, pharmacology and palliative care. CBD Science Group CEO Dr. Michael Raymont notes that the company’s strategy is unique and has been developed by experts who understand the regulatory framework and want the best for patients.
If this study yields positive outcomes regarding the analgesic attributes of marijuana, the entire cannabis sector including companies such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) will be vindicated in their conviction that the medicinal potential of cannabis is yet to be fully understood.
NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
